In this study, the first use of a bioresponsive polymer therapeutic agent in the promotion of corneal reepithelialisation after injury in an ex vivo whole-eye organ culture model was described. A polymereprotein conjugate consisting of dextrin and recombinant human epidermal growth factor was synthesised and applied as a single dose to a 2 mm ex vivo corneal ulcer, in culture. Enhanced wound healing was observed in response to dextrinerecombinant human epidermal growth factor, when exposed to a-amylase, compared with controls.
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In the context of polymereprotein conjugates, the stability and solubility of proteins can be enhanced, and their biological half-life and immunogenicity reduced, via polymer conjugation. 2 3 To this date, although polymer therapeutics have been licensed for use in humans (table 1), they have not been investigated widely in the field of corneal wound healing.
We have been developing a novel controlled release formulation of recombinant human epidermal growth factor (rhEGF), conjugated to the degradable polysaccharide, dextrin. 4 This provides a controlled delivery platform for the release of rhEGF in response to endogenous a-amylase, which is present in the tear film. 5 When conjugated to the dextrin polymer, the bioactivity of the growth factor is decreased, but an increase in protein stability is afforded. Bioactivity can be fully restored after polymer degradation by a-amylase, and the dextrin breakdown products, maltose, and isomaltose are further metabolised and/or excreted. 6 This Polymer-masking UnMasking Protein Therapy hypothesis 7 has been shown to stimulate dermal keratinocyte proliferation in vitro and enhances both the half-life of rhEGF and the stability in response to wound proteolysis. 4 In animal studies, EGF stimulated proliferation and DNA synthesis of corneal epithelium and increased the epithelial healing rate. 8e13 The initial hope of EGF to progress to a licensed product for clinical use in the early 1990s 14e16 did not come to fruition. The lack of significant effects from EGF, in humans, applied post penetrating keratoplasty 17 did not match the previous findings from animal studies. The aforementioned clinical studies have involved the repeated administration of EGF because of the short half-life and the action of the tear film.
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METHODS
We have evaluated the efficacy of single dose dextrinerhEGF in an ex vivo organ culture model of corneal wound healing. 19 20 The synthesis and characterisation of the conjugate was reproducible (figure 1). 4 Two-month-old male Wistar Han rats (250e300 g; Charles River Laboratories, Margate, UK) were sacrificed by CO 2 asphyxiation, confirmed by cervical dislocation. Wounding was performed within 1 h of sacrifice. The globe was irrigated with Balanced Salt Solution (BSS Plus Ò ; Alcon Laboratories, Hemel Hemstead, UK) containing 0.1% EDTA. A full-thickness 2 mm corneal abrasion was produced by excision. The globe was then enucleated. Tissue culture medium (DMEM supplemented with penicillin G, 100 U/ ml; streptomycin sulphate, 100 mg/ml; amphotericin B, 0.25 mg/ml; L-glutamine, 2 mM (Invitrogen, Paisley, UK): serum-free media (SFM)) was supplemented with study compounds, as shown in table 2, and added to the globes (n¼4). Specimens were maintained at 378C/5% CO 2 for 64 h. Wound healing was assessed by digital wound photography and fluorescein staining. After 64 h, globes were fixed in 10% formal saline, embedded in wax, sectioned and stained with H&E. Statistical analyses were undertaken using GraphPad Prism Ò , version 4.00 (GraphPad Software). Data were compared using a 1-way ANOVA, with a Bonferroni post test for group analysis. Results were expressed as a mean and SD. Statistical significance was considered at a probability of p<0.05.
RESULTS
This ex vivo model of corneal wound healing was sensitive to stimulation by fetal calf serum and by dextrinerhEGF. In the conjugated form, the rhEGF promoted a significant increase in the rate of corneal wound healing, with wound closure by 48 h, in the presence of human physiological levels of a-amylase compared with free rhEGF. With the addition of exogenous a-amylase, at physiological concentrations, rhEGF was released, or 'unmasked' from the polymer, thereby restoring bioactivity (figures 2 and 3).
There was a significant improvement in wound healing (p<0.006), in response to serum-containing medium (SCM; group 2), compared with the serum-free (SFM; group 1) and a-amylase (group 3) controls at 24 h (figure 4A). All wounds in the SCM group (group 2) had fully re-epithelialised by 48 h, while the average wound areas in the serum-free controls (groups 1 and 3) were 24.568.1% and 31.465%, respectively, of that at time 0 h (p<0.001). In the unconjugated rhEGF groups (groups 4 and 5), there were no significant effects on wound reepithelialisation (p>0.05) at either concentration and neither resulted in total wound re-epithelialisation. Wound areas at 64 h were 5.6611.3% and 23.4621.4% of the total wound area at time 0 h for the 10 mg/ml rhEGF and 1 mg/ml rhEGF groups, respectively (mean6SD) ( figure 4B ).
In the dextrinerhEGF conjugate study groups (groups 6e8), there was failed re-epithelialisation, in the absence of physiological concentrations of a-amylase (group 6; 'masked'), with an abrasion of 23.465.5% of that at time 0, persisting at 64 h. This was not significantly different to the SFM control (group 1) (p>0.05). Upon the addition of a-amylase (93 IU/l; 'unmasking'), there was a significant decrease in the wound area at 24 h in both the 1 mg/ml rhEGF equivalent (group 7) and 10 mg/ml rhEGF equivalent (group 8) groups (p<0.006). The dextrinerhEGF conjugate was significantly more effective at decreasing the wound area at 24 h at the lower dose (1 mg/ml rhEGF equivalent) than at the higher dose (10 mg/ml rhEGF equivalent) (p¼0.027) ( figure 4C ).
DISCUSSION
The increased efficacy of the dextrinerhEGF conjugate in enhancing corneal wound healing may be due to the sustained release phenomena. 4 In the ex vivo model described herein, the rhEGF was applied as a single dose at the outset of the experiment, and the free rhEGF may have been degraded because of the short half-life of EGF. 18 Although initial wound closure rates are similar in the first 24 h between rhEGF and dextrinerhEGF (+a-amylase), this apparent difference tailed off as time progressed. In the ex vivo organ culture model, the pharmacokinetics of EGF will differ but the sustained release of rhEGF from the a-amylase-mediated, degradation of the dextrinerhEGF conjugate may account for the enhanced wound healing in the Table 2 Culture medium supplementation dextrinerhEGF study groups. The ex vivo model of corneal wound healing has been shown to be reproducible and that it is a reliable model for further analysis of polymereprotein conjugates. This is the first application of polymer therapeutics specifically designed for tissue regeneration in such a model, and these preliminary investigations highlight the potential for the application of these therapeutics to enhance corneal wound healing. This application of a specific endogenous trigger to promote the controlled release of a bioactive peptide may be applied to the healing and/or regeneration of other tissues in the future. Figure 4 (A) Healing of the corneal wound (% reduction in wound area compared to 0 h) over 64 h in response to fetal calf serum (FCS) (serumcontaining media) and serum-free controls. There was a significant decrease (*p<0.006) in the wound area in response to FCS when compared with serum-free controls. (B) The corneal wound area reduction in response to free recombinant human epidermal growth factor (rhEGF). The initial rate of wound area reduction (over the first 24 h) was not significantly different (p>0.05) from FCS, but the effect was not sustained over 64 h. (C) The corneal wound area reduction in response to dextrinerhEGF. In the 'masked' (a-amylase-free) state, the bioactivity of dextrinerhEGF was reduced to that of serum-free controls (p>0.05), but upon the addition of a-amylase at physiological concentrations, bioactivity was significantly restored (**p<0.006). DextrinerhEGF was most effective at the 1 mg/ml concentration (***p¼0.027) compared with the conjugate at 10 mg/ml concentrations.
